

MATERIALS LICENSE

Amendment No. 15

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) and at the place(s) designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Sentara Bayside Hospital  
  
2. 800 Independence Boulevard  
P.O. Box 5695  
Virginia Beach, Virginia 23455-7003

In accordance with application dated February 27, 1996

3. License Number 45-16391-01

is amended in its entirety to read as follows:

4. Expiration Date July 31, 2001

5. Docket or Reference No. 030-10944

6. Byproduct, Source, and or Special Nuclear Material

7. Chemical and or Physical Form

8. Maximum Amount that Licensee May Possess at Any One Time Under This License

A. Any byproduct material identified in 10 CFR 35.100

A. Any radiopharmaceutical identified in 10 CFR 35.100

A. As needed

B. Any byproduct material identified in 10 CFR 35.200

B. Any radiopharmaceutical identified in 10 CFR 35.200

B. As needed

C. Any byproduct material identified in 10 CFR 31.11

C. Prepackaged kits

C. As needed

D. Iodine 131

D. Sodium iodide

D. As needed (Not to exceed 10 curies)

E. Any byproduct material identified in 10 CFR 35.500

E. Any diagnostic sealed source identified in 10 CFR 35.500 installed in a compatible device registered pursuant to 10 CFR 32.210

E. As needed

9. Authorized Use

A. Medical use described in 10 CFR 35.100

B. Medical use described in 10 CFR 35.200

C. In vitro testing

D. For the treatment of cardiac dysfunction and hyperthyroidism

E. Medical use described in 10 CFR 35.500

45-16391-01  
NRC APPROVAL  
10/10/00

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

45-16391-01

Docket or Reference Number

030-10944

Amendment No. 15

**CONDITIONS**

10. **Location of use:** Sentara Bayside Hospital  
800 Independence Boulevard  
Virginia Beach, Virginia
11. **Radiation Safety Officer:** John R. Olson, Jr., M.D., or in his absence David E. Weimer, M.S.
12. **Authorized users:**
- A. Andrew Ciric, M.D., for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - B. Lamar Smith, M.D., for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - C. R. Modlinger, M.D., for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, and 35.500.
  - D. Ralph R. Stephens, M.D. for medical uses identified in 10 CFR 35.100 and 31.11.
  - E. Robert L. Chiavarini, M.D. for medical uses identified in 10 CFR 35.100, 35.200 and 31.11.
  - F. Deborah A. Kuban, M.D. for iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - G. Anas M.El-Mahdi, M.D. for iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - H. Robert A. Woolfitt, M.D. for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - I. Donald W. Drew, M.D. for technetium 99m for cardiac studies.
  - J. David L. Weaver, M.D. for medical uses identified in 10 CFR 35.100, 35.200 and 31.11.
  - K. Robert M. Kesler, M.D. for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - L. Richard H. Miller, M.D. for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - M. David M. Bridges, M.D. for medical uses identified in 10 CFR 35.100, 35.200 and 31.11.
  - N. Elizabeth M. Higgins, M.D. for iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - O. George H. Christian, M.D. for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - P. Patsy J. Loiacono, M.D. for medical uses identified in 10 CFR 31.11, 10 CFR 35.100, 35.200, 35.500, and iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
  - Q. Andrew Heaton, M.D. for medical uses identified in 10 CFR 35.100 and 31.11.

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number

45-16391-01

Docket or Reference Number

050-10944

Amendment No. 15

(continued)

## CONDITIONS

- R. Ronald A. Stine, M.D. for technetium 99m for cardiac studies.
- S. Thomas D. Call, M.D. for technetium 99m for cardiac studies.
- T. John G. Kenerson, M.D. for technetium 99m for cardiac studies.
- U. Donald J. Lipskis, M.D. for technetium 99m for cardiac studies.
- V. Carter W. Taliaferro may use licensed material only as calibration and/or reference sources.
- W. Nai-Hsiang (David) Liu, Ph.D. may use licensed material only as calibration and/or reference sources.
- X. Janice Roman, M.D. for iodine 131 for the treatment of cardiac dysfunction and hyperthyroidism.
- Y. Stephen Carr, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism.
- Z. Nripendra Devanath, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism.
- A.A. Ronald L. King, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction.
- B.B. Susan McKenzie, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction.
- C.C. William F. Wheeler, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, and 31.11.
- D.D. John V. Whitbeck, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, and 31.11.
- E.E. Allison M. Smith, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, and 31.11.
- F.F. Lori Keith Taylor, M.D. for medical uses identified in 10 CFR 35.100, 35.200, 35.500, and 31.11.
- G.G. Rishi K. Saxena, M.D. for technetium 99m for cardiac imaging studies.
- H.H. John R. Olson, Jr., M.D. for medical uses identified in 10 CFR 35.100, 35.200, 31.11 and iodine 131 as iodide for treatment of hyperthyroidism and cardiac dysfunction.
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
14. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facility located at 800 Independence Boulevard, Virginia Beach, Virginia in accordance with the provisions of 10 CFR, Part 30.35(g) until this license is terminated by the Commission.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
45 16391-01

Docket or Reference Number  
030-10944

Amendment No. 15

(continued)

**CONDITIONS**

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 15, 1991
  - B. Letter dated July 22, 1991
  - C. Letter dated March 18, 1993 (change RSO, add authorized users)
  - D. Application dated February 16, 1994 (add area of use, delete authorized users and adds authorized users)
  - E. Application dated February 27, 1996 (Add Authorized User, Change RSO, Add Alternate RSO, and change dose calibrator testing procedures)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date **MAR 22 1996**

*Earl G. Wright*  
 Regional Director for Nuclear Material Safety  
 101 Marietta Street, N.W., Suite 500  
 Atlanta, Georgia 30333-1502